TolerRx

Sector:
Healthcare

Location:
Cambridge, MA

Year Funded:
2001

Website:
www.tolerx.com


Summary:
Tolerx, a world leader in the understanding of T cell function, is developing novel therapies intended to treat autoimmune diseases, diabetes, and cancer by specifically modulating T cell activity.  The company‚Äôs pipeline includes its lead candidate, otelixizumab, a targeted T cell immunomodulator in Phase 3 development for the treatment of type 1 diabetes that is partnered with GlaxoSmithKline.